poisar

Stocks · News reference

8-K filing — Matinas BioPharma Holdings, Inc. (MTNB)

SEC EDGAR

Filed: 2026-09-04 AccNo: 0001493152-26-041577 Size: 238 KB Item 3.01: Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing Item 8.01: Other Events Item 9.01: Financial Statements and Exhibits

More stocks newsConnected markets

Reference Details

Connected Markets

Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.

MTNB
Source
edgar
Observed
Checked
Cadence
Captured once, then retained as an archive reference
Status
fresh

Keep reading

  1. Na

    Matinas BioPharma Receives Notice of Non-Compliance with NYSE American Continued Listing Standards

    Matinas BioPharma received a notice from NYSE American on August 31, 2026, stating the company is not in compliance with continued listing standards due to stockholders' equity of $1.8 million (below the required $2.0 million threshold) and losses in five consecutive fiscal years. The company submitted a compliance plan accepted by NYSE American with a deadline of October 2, 2027. Shares will continue trading during the plan period, but delisting proceedings may be initiated if compliance is not achieved.

    MTNB